A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.

NCT05016323 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

316

Enrollment

INDUSTRY

Sponsor class

Conditions

IgA Nephropathy

Interventions

DRUG: HR19042 Capsules
DRUG: Placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.